Nurix Therapeutics
NRIX
172 hedge funds and large institutions have $1.53B invested in Nurix Therapeutics in 2024 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 66 increasing their positions, 58 reducing their positions, and 29 closing their positions.
52% more call options, than puts
Call options by funds: $1.84M | Put options by funds: $1.21M
14% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 58
12% more capital invested
Capital invested by funds: $1.36B → $1.53B (+$169M)
1% less funds holding
Funds holding: 173 → 172 (-1)
3% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 29
4.18% less ownership
Funds ownership: 109.57% → 105.39% (-4.2%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$37.4M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
+$13.9M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$12.8M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$12.5M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$22.4M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$13.6M |
| 3 |
Millennium Management
New York
|
-$8.56M |
| 4 |
State Street
Boston,
Massachusetts
|
-$7.64M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$6.97M |
NRIX Hedge Fund Activity: Q3 2024 in Review
172 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q3 2024, worth a combined $1.53B — up 12% from $1.36B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of NRIX and 28 opened new positions — a net loss of 1 holder — while 58 trimmed existing stakes and 66 added.
The largest buyer was Commodore Capital, opening a new position worth an estimated $37.4M. The largest seller was Soleus Capital Management, cutting an estimated $22.4M.
- 172 institutional investors held Nurix Therapeutics (NRIX) as of Q3 2024, down from 173 in Q2 2024.
- Funds reported $1.53B of Nurix Therapeutics stock for Q3 2024, up 12% quarter-over-quarter.
- 28 funds opened new Nurix Therapeutics positions in Q3 2024 and 29 closed out, a net change of -1 holder.
- The largest Nurix Therapeutics buyer in Q3 2024 was Commodore Capital, an estimated $37.4M added.
- The largest Nurix Therapeutics seller in Q3 2024 was Soleus Capital Management, an estimated $22.4M sold.
Based on aggregated 13F filings for Q3 2024.